ライフサイエンスコーパス: iodixanol

1 within 3 days after contrast administration (iodixanol).

2 after the administration of contrast medium (iodixanol).

3 ngiotensin II were significantly affected by iodixanol.

4 ctivity in afferent arterioles perfused with iodixanol.

5 ce, perfused with either vehicle solution or iodixanol (23 mg of iodine per milliliter) for 20 minute

6 andard deviation were comparable between the iodixanol 270 and iopromide 300 contrast media groups (4

7 for the lower iodine concentration, the mean iodixanol 270 bolus was larger compared with that of iop

8 Although in the iodixanol 270 group patients experienced less heat disco

9 ivery rates, the iso-osmolar contrast medium iodixanol 270 is not inferior to low-osmolar contrast me

10 spectively randomized to receive iso-osmolar iodixanol 270 or low-osmolar iopromide 300 contrast medi

11 Iodixanol 270 was associated with less heat discomfort,

12 ide synthase inhibition after perfusion with iodixanol (3.3 microm and 4.3 microm vs 7.5 microm [cont

13 of the iso-osmolar contrast material (IOCM) iodixanol 320 and patients who underwent a noncontrast c

14 A 130-mL dose of iodixanol 320 was injected intravenously at a rate of 4

15 In patients with CKD 6-8 mL of Iodixanol (320 mg/mL) diluted with saline to 18-24 mL wa

16 a water-soluble contrast material-enhanced (iodixanol, 320 mg of iodine per milliliter) esophagram w

17 positive, 21 (50%) to Iomeprol, 7 (16.7%) to Iodixanol, 5 (11.9%) to Iobitridol, 4 (9.5%) to Ioxaglat

18 %) that were skin-test negative, 38 (76%) to Iodixanol, 8 (16%) to Iomeprol and 4 (8%) to Iohexol.

19 events at 30 days in patients randomized to iodixanol (9.1% versus 13.2% for ioxaglate, P=0.07).

20 cess was more frequent in patients receiving iodixanol (92.2% versus 85.9% for ioxaglate, P=0.004).

21 With iodixanol, afferent arteriole diameters were significant

22 aterial (59 who underwent CT with iohexol or iodixanol and 81 who underwent MR imaging with gadopente

23 Angiotensin II responses were enhanced by iodixanol and by nitric oxide synthase inhibition after

24 ed iodine-containing contrast agents such as iodixanol and iopromide for angiography.

25 ntrolled by changing the volumetric ratio of iodixanol and the purification solutions (iodixanol-Kyot

26 onation techniques, NaBr gradients, isotonic iodixanol, and sucrose gradient centrifugation.

27 We present Iodixanol as a non-toxic medium supplement that allows r

28 Thus, the iodixanol-based method can be used not only to improve t

29 Iodixanol caused a modest but statistically significant

30 were purified by serial salt-Percoll-sucrose-iodixanol centrifugation, resulting in two bands with di

31 sk with the iso-osmolar contrast media agent iodixanol compared with a diverse group of LOCM that jus

32 d point was less frequent in those receiving iodixanol compared with those receiving ioxaglate (5.4%

33 Our data suggest that using an iodixanol-controlled density gradient improves the islet

34 his study, we evaluated the effectiveness of iodixanol-controlled density gradients on the islet puri

35 Iodixanol decreased SCr (mean +/- standard deviation) fr

36 ites were fractionated by modification of an iodixanol density gradient method previously used for ac

37 tionation of the small membrane pellet on an iodixanol density gradient, the gene 1 proteins p28 and

38 eparate membrane substructures of the AJC in iodixanol density gradients and define their protein con

39 n this paper, we describe a new method using iodixanol density gradients for purification of the acid

40 Purification of the volutin granules using iodixanol density gradients indicated a preferential loc

41 ication of the electron-dense vacuoles using iodixanol density gradients indicated a preferential loc

42 With iodixanol, DHE fluorescence ratio was increased by 12% (

43 fying recombinant adenovectors in two steps: iodixanol discontinuous density gradient ultracentrifuga

44 All patients who underwent an iodixanol-enhanced (IOCM group) or a noncontrast (noncon

45 The cohort receiving the nonionic dimer iodixanol experienced a 45% reduction in in-hospital MAC

46 tcontrast AKI, intravenous administration of iodixanol for contrast material enhanced CT was not an i

47 Protease-protection experiments and iodixanol gradient analysis suggest some beta-actin and

48 onates with endosome markers and BACE1 in an iodixanol gradient and displays extensive colocalization

49 lysis, either in situ or when purified using iodixanol gradient centrifugation.

50 ization of COPII vesicles fractionated on an iodixanol gradient revealed that HCV RNA is enriched in

51 yed similar biophysical properties following iodixanol gradient ultracentrifugation.

52 Combining polyethylene glycol precipitation, iodixanol gradient, and size-exclusion chromatography, w

53 of PNS-derived membranes isolated on a 9-30% Iodixanol gradient, the activity, as measured by CT-A1 p

54 Samples were fractionated on iodixanol gradients and cushions.

55 Purification of acidocalcisomes using iodixanol gradients indicated co-localization of the H(+

56 y their behavior upon upward floatation into iodixanol gradients or by immuno-isolation.

57 Iodixanol gradients were shown to best preserve host lip

58 ients, equilibrium density centrifugation in iodixanol gradients, and immunofluorescence confocal mic

59 ere isolated by subcellular fractionation in iodixanol gradients, showed a high concentration of basi

60 ssed ERManI migrate at an ER-like density on iodixanol gradients, suggesting that the QCVs are derive

61 o subcellular fractionation on discontinuous Iodixanol gradients.

62 Fewer patients in the iodixanol group (8.5%) than in the iopromide group (27.8

63 inistration was significantly smaller in the iodixanol group compared with the LOCM group (0.06 mg/dl

64 inistration, occurred less frequently in the iodixanol group than in the LOCM group in all patients (

65 Iodixanol had a slightly lower risk for CIN than LOCM, b

66 h that of the iso-osmolality contrast medium iodixanol in high-risk patients.

67 ed, double-blind comparison of iopamidol and iodixanol in patients with chronic kidney disease (estim

68 Iodixanol increased and iopromide decreased GFR on all 3

69 Iodixanol increased average attenuation by 7 HU (P <.05)

70 Nitric oxide synthase inhibition augmented iodixanol-induced constriction, with diameters reduced f

71 out with different CM (iobitridol, iomeprol, iodixanol, iohexol, ioversol, iopramide and ioxaglate).

72 ,727 patients indicates that use of the IOCM iodixanol is associated with smaller rises in Cr and low

73 of iodixanol and the purification solutions (iodixanol-Kyoto [IK] solutions).

74 ate that different properties of sucrose and iodixanol membrane flotation gradients may explain some

75 patients received either intra-arterial IOCM iodixanol (n = 1,382) or LOCM (n = 1,345) were included.

76 trast-enhanced CT with either iso-osmolality iodixanol (n = 61) or low-osmolality iopromide (n = 56).

77 was to compare the isosmolar nonionic dimer iodixanol (n=405) with the low osmolar ionic agent ioxag

78 gression of randomized, controlled trials of iodixanol, no relationship was found between route of ad

79 A more pronounced effect of iodixanol on afferent than on efferent arterioles may co

80 The stocks can be purified by an iodixanol (OptiPrep) gradient centrifugation procedure t

81 mics at baseline and after administration of iodixanol or iopamidol contrast.

82 iopamidol and 13.0% (12 of 92 patients) with iodixanol (P=0.11), whereas SCr increases > or = 25% wer

83 opamidol and 6.7% (14 of 210 patients) after iodixanol (P=0.39), whereas rates of SCr increases > or

84 Iodixanol provides an easy and affordable solution to a

85 same pulse/chase protocols were followed by iodixanol subcellular fractionation, extraction of lipop

86 ontrast material administration are lower in iodixanol than iopromide groups.

87 intraarterial administration of iopamidol or iodixanol to high-risk patients, with or without diabete

88 DAF-FM fluorescence increased less during iodixanol treatment and nitric oxide synthase inhibition

89 confirmed by velocity sedimentation through iodixanol, which effectively separated membrane microves

90 stinct negative gravitropism in solutions of iodixanol with densities of 1.052 to 1.320 as well as in

91 toxicity of isosmolar contrast medium (IOCM) iodixanol with low-osmolar contrast media (LOCM) and to